American Century Companies Inc. Grows Position in Alphatec Holdings, Inc. (NASDAQ:ATEC)

American Century Companies Inc. lifted its holdings in Alphatec Holdings, Inc. (NASDAQ:ATEC) by 36.5% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 4,989,057 shares of the medical technology company’s stock after purchasing an additional 1,334,780 shares during the period. American Century Companies Inc. owned about 3.52% of Alphatec worth $45,800,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. R Squared Ltd purchased a new stake in Alphatec during the fourth quarter worth $29,000. Nisa Investment Advisors LLC lifted its stake in shares of Alphatec by 973.3% during the 4th quarter. Nisa Investment Advisors LLC now owns 4,669 shares of the medical technology company’s stock worth $43,000 after purchasing an additional 4,234 shares during the last quarter. Newton One Investments LLC purchased a new stake in shares of Alphatec during the 4th quarter worth $50,000. XTX Topco Ltd purchased a new position in Alphatec in the third quarter valued at about $69,000. Finally, AlphaQuest LLC purchased a new position in Alphatec in the fourth quarter valued at about $80,000. 66.35% of the stock is currently owned by institutional investors.

Alphatec Stock Down 2.0 %

Alphatec stock opened at $10.05 on Friday. The business’s 50-day simple moving average is $10.89 and its two-hundred day simple moving average is $8.93. The company has a debt-to-equity ratio of 30.21, a quick ratio of 1.15 and a current ratio of 2.32. The company has a market cap of $1.45 billion, a PE ratio of -7.85 and a beta of 1.39. Alphatec Holdings, Inc. has a fifty-two week low of $4.88 and a fifty-two week high of $14.54.

Alphatec (NASDAQ:ATEC) last issued its earnings results on Wednesday, February 26th. The medical technology company reported ($0.23) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.04). Alphatec had a negative net margin of 31.06% and a negative return on equity of 541.39%. The firm had revenue of $176.79 million during the quarter, compared to analysts’ expectations of $172.74 million. Equities analysts anticipate that Alphatec Holdings, Inc. will post -1.08 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on the stock. Piper Sandler raised their price target on shares of Alphatec from $12.00 to $13.00 and gave the company an “overweight” rating in a report on Thursday, February 27th. Needham & Company LLC restated a “buy” rating and issued a $16.00 target price on shares of Alphatec in a research note on Thursday, February 27th. Barclays upped their price target on Alphatec from $20.00 to $21.00 and gave the stock an “overweight” rating in a research report on Wednesday, January 22nd. StockNews.com raised Alphatec from a “sell” rating to a “hold” rating in a research report on Friday, February 28th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $20.00 target price on shares of Alphatec in a research report on Tuesday, January 14th. Two research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat, Alphatec currently has a consensus rating of “Moderate Buy” and a consensus price target of $17.67.

Insider Transactions at Alphatec

In other Alphatec news, EVP David Sponsel sold 58,283 shares of the stock in a transaction dated Monday, January 13th. The stock was sold at an average price of $10.71, for a total transaction of $624,210.93. Following the sale, the executive vice president now directly owns 502,311 shares of the company’s stock, valued at approximately $5,379,750.81. This trade represents a 10.40 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Patrick Miles sold 50,000 shares of the business’s stock in a transaction dated Wednesday, January 29th. The shares were sold at an average price of $12.03, for a total value of $601,500.00. Following the completion of the transaction, the chief executive officer now directly owns 6,152,544 shares of the company’s stock, valued at approximately $74,015,104.32. This trade represents a 0.81 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 337,321 shares of company stock worth $3,828,060 over the last 90 days. 22.80% of the stock is currently owned by company insiders.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.